These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
665 related articles for article (PubMed ID: 28945841)
1. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy. Sánchez-Paulete AR; Teijeira A; Cueto FJ; Garasa S; Pérez-Gracia JL; Sánchez-Arráez A; Sancho D; Melero I Ann Oncol; 2017 Dec; 28(suppl_12):xii44-xii55. PubMed ID: 28945841 [TBL] [Abstract][Full Text] [Related]
2. Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen. Wculek SK; Amores-Iniesta J; Conde-Garrosa R; Khouili SC; Melero I; Sancho D J Immunother Cancer; 2019 Apr; 7(1):100. PubMed ID: 30961656 [TBL] [Abstract][Full Text] [Related]
3. Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 Zhou Y; Slone N; Chrisikos TT; Kyrysyuk O; Babcock RL; Medik YB; Li HS; Kleinerman ES; Watowich SS J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32273347 [TBL] [Abstract][Full Text] [Related]
4. Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment. Fu C; Jiang A Front Immunol; 2018; 9():3059. PubMed ID: 30619378 [TBL] [Abstract][Full Text] [Related]
5. Sialic acid removal from dendritic cells improves antigen cross-presentation and boosts anti-tumor immune responses. Silva M; Silva Z; Marques G; Ferro T; Gonçalves M; Monteiro M; van Vliet SJ; Mohr E; Lino AC; Fernandes AR; Lima FA; van Kooyk Y; Matos T; Tadokoro CE; Videira PA Oncotarget; 2016 Jul; 7(27):41053-41066. PubMed ID: 27203391 [TBL] [Abstract][Full Text] [Related]
6. Dendritic Cells and Cancer Immunity. Gardner A; Ruffell B Trends Immunol; 2016 Dec; 37(12):855-865. PubMed ID: 27793569 [TBL] [Abstract][Full Text] [Related]
7. Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Groh V; Li YQ; Cioca D; Hunder NN; Wang W; Riddell SR; Yee C; Spies T Proc Natl Acad Sci U S A; 2005 May; 102(18):6461-6. PubMed ID: 15824323 [TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibodies targeted against melanoma and ovarian tumors enhance dendritic cell-mediated cross-presentation of tumor-associated antigens and efficiently cross-prime CD8+ T cells. Cioca DP; Deak E; Cioca F; Paunescu V J Immunother; 2006; 29(1):41-52. PubMed ID: 16365599 [TBL] [Abstract][Full Text] [Related]
9. Influenza A infection enhances cross-priming of CD8+ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion. Wei J; Waithman J; Lata R; Mifsud NA; Cebon J; Kay T; Smyth MJ; Sadler AJ; Chen W J Immunol; 2010 Nov; 185(10):6013-22. PubMed ID: 20956347 [TBL] [Abstract][Full Text] [Related]
10. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity. Noubade R; Majri-Morrison S; Tarbell KV Front Immunol; 2019; 10():1014. PubMed ID: 31143179 [TBL] [Abstract][Full Text] [Related]
11. In vivo depletion of DC impairs the anti-tumor effect of agonistic anti-CD137 mAb. Murillo O; Dubrot J; Palazón A; Arina A; Azpilikueta A; Alfaro C; Solano S; Ochoa MC; Berasain C; Gabari I; Pérez-Gracia JL; Berraondo P; Hervás-Stubbs S; Melero I Eur J Immunol; 2009 Sep; 39(9):2424-36. PubMed ID: 19662633 [TBL] [Abstract][Full Text] [Related]
12. Plasmacytoid dendritic cells cross-prime naive CD8 T cells by transferring antigen to conventional dendritic cells through exosomes. Fu C; Peng P; Loschko J; Feng L; Pham P; Cui W; Lee KP; Krug AB; Jiang A Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23730-23741. PubMed ID: 32879009 [TBL] [Abstract][Full Text] [Related]
13. Clinically applicable CD34 van Eck van der Sluijs J; van Ens D; Thordardottir S; Vodegel D; Hermens I; van der Waart AB; Falkenburg JHF; Kester MGD; de Rink I; Heemskerk MHM; Borst J; Schaap NPM; Jansen JH; Xiao Y; Dolstra H; Hobo W Cancer Immunol Immunother; 2021 Nov; 70(11):3167-3181. PubMed ID: 33796917 [TBL] [Abstract][Full Text] [Related]
14. Coupled for cross-presentation in tumor immunotherapy. Pang B; Neefjes J Sci Transl Med; 2010 Aug; 2(44):44ps40. PubMed ID: 20702855 [TBL] [Abstract][Full Text] [Related]
18. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How? Cancel JC; Crozat K; Dalod M; Mattiuz R Front Immunol; 2019; 10():9. PubMed ID: 30809220 [TBL] [Abstract][Full Text] [Related]